BENELYTE SOLUTION FOR INFUSION

2. What you need to know before you use Benelyte

Do not use Benelyte

• if your child is allergic (hypersensitive) to sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, glucose, or any of the other components of this medicine (listed in section 6).
• For premature newborns and neonates (≤28 days of age): Your child should not receive a certain antibiotic called ceftriaxone as an intravenous infusion at the same time as this medicine.
• if your child has excess water in their body (hyperhydration)

Warnings and Precautions

Tell your doctor, pharmacist, or nurse before your child is given Benelyte if your child has:

• less acid in the body than normal (metabolic alkalosis)
• abnormally high blood sugar levels (hyperglycemia)
• abnormally low potassium levels in the blood (hypokalemia)
• abnormally high sodium levels in the blood (hypernatremia)
• abnormally high chloride levels in the blood (hyperchloremia)
• kidney failure or decreased kidney function
• has been treated with a certain antibiotic called ceftriaxone; it must not be mixed or administered simultaneously with any solution containing calcium given by intravenous infusion. Your doctor is aware of this and will not administer them together, either through different infusion lines or different infusion sites.
• • However, in children over 28 days, your doctor may administer calcium and ceftriaxone sequentially, one after the other, if infusion lines are used at different sites or if the infusion lines are replaced or if they are thoroughly flushed with physiological saline solution between infusions, to avoid precipitation. If you or your child suffer from low blood volume, your doctor will avoid administering calcium and ceftriaxone sequentially.

While your child is being given this medicine, the levels of electrolytes in the blood, water balance, blood glucose levels, and acid-base status should be monitored from time to time.

When administering the medicine, caution should be exercised in children, especially in newborns and infants, as lactic acidosis (an increase in lactic acid in the body) may occur. This should be taken into consideration in children born with problems using lactate.

Using Benelyte with other medicines

Tell your doctor or pharmacist if your child is using, has recently used, or might use any other medicines.

Concomitant use with ceftriaxone (an antibiotic) is not recommended when administered intravenously (see section Warnings and Precautions).

Pregnancy and Breastfeeding

Benelyte is for use in children only (under 14 years of age).

3. How to use Benelyte

Your doctor or another healthcare professional will give your child this medicine by infusion into a vein (intravenous drip).

Dose

The doctor will decide the amount of medicine to be given to your child, depending on their age, weight, clinical condition, and other treatment they are receiving. The individual needs for fluids, electrolytes, and energy will be taken into account. Your doctor will decide the correct dose for your child.

Follow exactly the administration instructions of Benelyte given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

If you use more Benelyte than you should

It is unlikely that your child will be given an incorrect dose, as the medicine will be administered by a doctor or another healthcare professional.

An overdose may cause excess fluid in the body (hyperhydration) and excess sugar in the blood (hyperglycemia).

The doctor will determine the appropriate treatment to normalize your child's condition, which may include stopping the infusion, monitoring the salt levels in your child's blood, and administering appropriate medications to treat the symptoms (e.g., diuretics, insulin).

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Frequency not known(cannot be estimated from the available data)

Local reactions at the injection site due to the administration technique:

• fever (febrile response)
• infection at the infusion site
• irritation and inflammation of the vein into which the solution is infused (phlebitis). This can cause redness, pain, or burning and inflammation along the vein into which the solution is being administered
• formation of a blood clot (thrombosis) at the infusion site, causing pain, swelling, or redness in the area of the clot
• leakage of the infusion solution into the tissues surrounding the vein (extravasation). This can damage tissues and cause scarring.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Benelyte

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label or carton after EXP. The expiry date refers to the last day of the month stated.

This medicine does not require any special storage conditions.

Use only if the solution is clear, without visible particles, and if the container is not damaged.

Use immediately after the first opening. From a microbiological point of view, the product should be used immediately. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not be more than 24 hours at 2°C-8°C, unless the storage and opening are performed under controlled and validated aseptic conditions.

When combined with other infusion solutions, the current general guidelines for the administration of total fluids should be taken into account for the calculation of the dose for the corresponding age group.

The individual needs for water, electrolytes, and carbohydrates should be calculated and replaced accordingly; in particular, in premature newborns, low birth weight, and also in all other exceptional therapeutic situations. The balance needs to be more accurate in premature patients, in the youngest, and in those with low weight.

Form of administration

Intravenous route.

Duration of administration

The duration of administration depends on the patient's needs for fluids and electrolytes.

Incompatibilities

The compatibility of the medicines to be added to Benelyte should be evaluated before addition. In general, it can be stated that the following medicines (groups) should not be mixed with Benelyte:

• Medicines that could form poorly soluble precipitates with the constituents of the solution. (The preparation contains Ca2+ ions. Precipitation may occur with the addition of inorganic phosphate, hydrogen carbonate/carbonate, or oxalate).
• Medicines that are not stable in an acidic pH range or do not have optimal efficacy or that decompose

Infusion solutions containing glucose should not be administered simultaneously in the same infusion equipment with blood due to the possibility of pseudo-agglutination.

6. Contents of the pack and other information

Composition of Benelyte:

Each ml of Benelyte solution for infusion contains:

Sodium Chloride 6.429 mg

Potassium Chloride 0.298 mg

Calcium Chloride Dihydrate 0.147 mg

Magnesium Chloride Hexahydrate 0.203 mg

Sodium Acetate Trihydrate 4.082 mg

Glucose Monohydrate 11.0 mg

(equivalent to Glucose 10.0 mg)

The other ingredients are: hydrochloric acid 37% (for pH adjustment), sodium hydroxide (for pH adjustment), and water for injections.

Appearance and pack contents

Benelyte is a clear, colorless to slightly yellowish aqueous solution for infusion.

Benelyte is available in low-density polyethylene (KabiPac) bottles of 100 ml, 250 ml, and 500 ml as the primary packaging, closed with a polyethylene or polyethylene/polypropylene plug with a polyisoprene seal.

Pack sizes:

40 x 100 ml bottles

20 x 250 ml bottles

10 x 500 ml bottles

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Fresenius Kabi España, S.A.U.

Marina 16-18,

08005-Barcelona

Manufacturer

Fresenius Kabi Polska Sp. z o.o.

ul. Sienkiewicza 25,

PL-99-300 Kutno

Poland

This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Date of last revision of this leaflet: August 2023

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

-----------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals

For more information, consult the Summary of Product Characteristics.

Posology

The dose for perioperative intravenous infusion therapy depends on the needs for fluids, electrolytes, and glucose:

During the first hour, for example, 10 to 20 ml/kg/hour, and then adjust the infusion rate according to the basic requirements and correction with monitoring of relevant cardiovascular and laboratory parameters.

The following reference values apply to fluid needs:

Newborns (from 0 to ≤28 days), infants (28 days to ≤1 year):

100 - 140 ml/kg body weight/day

Infants from 1 to ≤ 2 years:

80 - 120 ml/kg body weight/day

Children from 2 to ≤ 5 years:

80 - 100 ml/kg body weight/day

Children from 5 to ≤ 10 years:

60 - 80 ml/kg body weight/day

Children from 10 to ≤12 years and adolescents from 12 to ≤14 years:

50 - 70 ml/kg body weight/day

For short-term intravascular volume replacement, the dose should be administered individually according to fluid needs.

For the treatment of isotonic dehydration in the pediatric population, the infusion rate and daily dose should be determined individually according to the nature and severity of the hydroelectrolytic imbalance by monitoring relevant cardiovascular and laboratory parameters.

If Benelyte is used in combination with other infusion solutions, the current guidelines for the administration of total fluids should be taken into account for the calculation of the dose for the corresponding age group.

The individual needs for water, electrolytes, and carbohydrates should be calculated and replaced accordingly; in particular, in premature newborns, low birth weight, and also in all other exceptional therapeutic situations. The balance needs to be more accurate in premature patients, in the youngest, and in those with low weight.

Form of administration

Intravenous route.

Duration of administration

The duration of administration depends on the patient's needs for fluids and electrolytes.

Incompatibilities

The compatibility of the medicines to be added to Benelyte should be evaluated before addition. In general, it can be stated that the following medicines (groups) should not be mixed with Benelyte:

• Medicines that could form poorly soluble precipitates with the constituents of the solution. (The preparation contains Ca2+ ions. Precipitation may occur with the addition of inorganic phosphate, hydrogen carbonate/carbonate, or oxalate).
• Medicines that are not stable in an acidic pH range or do not have optimal efficacy or that decompose

Infusion solutions containing glucose should not be administered simultaneously in the same infusion equipment with blood due to the possibility of pseudo-agglutination.